Furthermore, the relatively weak and even nonsignificant correlations were observed between immune checkpoints and pathological stage or KRAS/TP53 expression, respectively (Figure S1G), which further implicated that immune checkpoints themselves might not be ideal targets for pancreatic cancer. The gene discussed is KRAS; the disease is pancreatic neoplasm.